Literature DB >> 18582997

Alphavirus replicon particles acting as adjuvants promote CD8+ T cell responses to co-delivered antigen.

Joseph M Thompson1, Alan C Whitmore, Herman F Staats, Robert E Johnston.   

Abstract

Alphavirus replicon particles induce strong antibody and CD8+ T cell responses to expressed antigens in numerous experimental systems. We have recently demonstrated that Venezuelan equine encephalitis virus replicon particles (VRP) possess adjuvant activity for systemic and mucosal antibody responses. In this report, we demonstrate that VRP induced an increased and balanced serum IgG subtype response to co-delivered antigen, with simultaneous induction of antigen-specific IgG1 and IgG2a antibodies, and increased both systemic and mucosal antigen-specific CD8+ T cell responses, as measured by an IFN-gamma ELISPOT assay. Additionally, VRP further increased antigen-specific T cell immunity in an additive fashion following co-delivery with the TLR ligand, CpG DNA. VRP infection led to recruitment of CD8+ T cells into the mucosal compartment, possibly utilizing the mucosal homing receptor, as this integrin was upregulated on CD8+ T cells in the draining lymph node of VRP-infected animals, where VRP-infected dendritic cells reside. This newly recognized ability of VRP to mediate increased T cell response towards co-delivered antigen provides the potential to both define the molecular basis of alphavirus-induced immunity, and improve alphavirus-based vaccines.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18582997      PMCID: PMC3608392          DOI: 10.1016/j.vaccine.2008.05.046

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  53 in total

Review 1.  Immunologic correlates of protection induced by vaccination.

Authors:  S A Plotkin
Journal:  Pediatr Infect Dis J       Date:  2001-01       Impact factor: 2.129

Review 2.  Alphavirus-based vaccines.

Authors:  Kenneth Lundstrom
Journal:  Curr Opin Mol Ther       Date:  2002-02

Review 3.  Antigen degradation or presentation by MHC class I molecules via classical and non-classical pathways.

Authors:  Monique Grommé; Jacques Neefjes
Journal:  Mol Immunol       Date:  2002-10       Impact factor: 4.407

Review 4.  Alphavirus vectors and vaccination.

Authors:  Jonathan O Rayner; Sergey A Dryga; Kurt I Kamrud
Journal:  Rev Med Virol       Date:  2002 Sep-Oct       Impact factor: 6.989

Review 5.  Alphavirus replicon particles as candidate HIV vaccines.

Authors:  Nancy L Davis; Ande West; Elizabeth Reap; Gene MacDonald; Martha Collier; Sergey Dryga; Maureen Maughan; Mary Connell; Chris Walker; Kathryn McGrath; Chad Cecil; Li-Hua Ping; Jeff Frelinger; Robert Olmsted; Paula Keith; Ronald Swanstrom; Carolyn Williamson; Philip Johnson; David Montefiori; Robert E Johnston
Journal:  IUBMB Life       Date:  2002 Apr-May       Impact factor: 3.885

6.  Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles.

Authors:  N L Davis; I J Caley; K W Brown; M R Betts; D M Irlbeck; K M McGrath; M J Connell; D C Montefiori; J A Frelinger; R Swanstrom; P R Johnson; R E Johnston
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

7.  Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles.

Authors:  Patrick R Harrington; Boyd Yount; Robert E Johnston; Nancy Davis; Christine Moe; Ralph S Baric
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

Review 8.  Alphavirus DNA and particle replicons for vaccines and gene therapy.

Authors:  J M Polo; J P Gardner; Y Ji; B A Belli; D A Driver; S Sherrill; S Perri; M A Liu; T W Dubensky
Journal:  Dev Biol (Basel)       Date:  2000

9.  Evaluation of FIV protein-expressing VEE-replicon vaccine vectors in cats.

Authors:  Mary Jo Burkhard; Loretta Valenski; Sarah Leavell; Gregg A Dean; Wayne A F Tompkins
Journal:  Vaccine       Date:  2002-12-13       Impact factor: 3.641

10.  Specific restrictions in the progression of Venezuelan equine encephalitis virus-induced disease resulting from single amino acid changes in the glycoproteins.

Authors:  F B Grieder; N L Davis; J F Aronson; P C Charles; D C Sellon; K Suzuki; R E Johnston
Journal:  Virology       Date:  1995-02-01       Impact factor: 3.616

View more
  22 in total

1.  A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge.

Authors:  Meagan Bolles; Damon Deming; Kristin Long; Sudhakar Agnihothram; Alan Whitmore; Martin Ferris; William Funkhouser; Lisa Gralinski; Allison Totura; Mark Heise; Ralph S Baric
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

2.  Infected dendritic cells are sufficient to mediate the adjuvant activity generated by Venezuelan equine encephalitis virus replicon particles.

Authors:  Daniel R Tonkin; Alan Whitmore; Robert E Johnston; Mario Barro
Journal:  Vaccine       Date:  2012-04-21       Impact factor: 3.641

3.  Design of chimeric alphaviruses with a programmed, attenuated, cell type-restricted phenotype.

Authors:  Dal Young Kim; Svetlana Atasheva; Niall J Foy; Eryu Wang; Elena I Frolova; Scott Weaver; Ilya Frolov
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

4.  A mucosal adjuvant for the inactivated poliovirus vaccine.

Authors:  Benjamin P Steil; Patricia Jorquera; Janny Westdijk; Wilfried A M Bakker; Robert E Johnston; Mario Barro
Journal:  Vaccine       Date:  2013-12-13       Impact factor: 3.641

5.  Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study.

Authors:  Erika J Crosby; William Gwin; H Kim Lyerly; Zachary C Hartman; Kimberly Blackwell; Paul K Marcom; Serena Chang; Holden T Maecker; Gloria Broadwater; Terry Hyslop; Sungjin Kim; Andre Rogatko; Veronica Lubkov; Joshua C Snyder; Takuya Osada; Amy C Hobeika; Michael A Morse
Journal:  Clin Cancer Res       Date:  2019-01-11       Impact factor: 12.531

6.  Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge.

Authors:  Anna D LoBue; Joseph M Thompson; Lisa Lindesmith; Robert E Johnston; Ralph S Baric
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

7.  Pseudoinfectious Venezuelan equine encephalitis virus: a new means of alphavirus attenuation.

Authors:  Svetlana Atasheva; Dal Young Kim; Maryna Akhrymuk; David G Morgan; Elena I Frolova; Ilya Frolov
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

8.  Vaccine Platforms to Control Arenaviral Hemorrhagic Fevers.

Authors:  Ricardo Carrion; Peter Bredenbeek; Xiaohong Jiang; Irina Tretyakova; Peter Pushko; Igor S Lukashevich
Journal:  J Vaccines Vaccin       Date:  2012-11-20

9.  Chimeric GII.4 norovirus virus-like-particle-based vaccines induce broadly blocking immune responses.

Authors:  Kari Debbink; Lisa C Lindesmith; Eric F Donaldson; Jesica Swanstrom; Ralph S Baric
Journal:  J Virol       Date:  2014-04-16       Impact factor: 5.103

10.  Immunogenicity and efficacy of alphavirus-derived replicon vaccines for respiratory syncytial virus and human metapneumovirus in nonhuman primates.

Authors:  John T Bates; Jennifer A Pickens; Jennifer E Schuster; Monika Johnson; Sharon J Tollefson; John V Williams; Nancy L Davis; Robert E Johnston; Nancy Schultz-Darken; James C Slaughter; Frances Smith-House; James E Crowe
Journal:  Vaccine       Date:  2016-01-07       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.